GForce Life Sciences

gforcelifesciences.com

GForce Life Sciences
GForce Life Sciences matches highly targeted consultants and direct hire candidates to executives'​ needs. Regulatory pressures, altering market demands and healthcare refinement are changing the landscape of the global life sciences industry. Patients, providers, payers, and regulators are seeking a higher quality of care and better therapeutic benefits, along with reduced costs and enhanced transparency.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GILEAD, WORKING ON ITS OWN REMDESIVIR RAMP-UP, SCOUTS LICENSING PARTNERS FOR GLOBAL PRODUCTION

Fiercepharma | May 06, 2020

news image

Gilead Sciences can only produce so much of its newly authorized COVID-19 drug remdesivir, so it’s scouting other companies to bolster global supply. Even as it presses ahead with its own remdesivir ramp-up, Gilead says it’s in licensing talks with the “world’s leading chemical and pharmaceutical manufacturing companies” about their ability to produce remdesivir for countries in Europe, Asia and beyond until at least 2022. Remdesivir manufacturing relies on “s...

Read More

PHARMACY MARKET

BOSTON SCIENTIFIC ANNOUNCES PARTNERSHIP DEFINITIVE AGREEMENT TO DIVEST BTG SPECIALTY PHARMACEUTICALS BUSINESS

Boston Scientific | December 02, 2020

news image

Boston Scientific Corporation today declared that it has gone into a conclusive concurrence with Stark International Lux S.A.R.L., and SERB SAS, partners of SERB, an European strength drug gathering, to sell its BTG Specialty Pharmaceuticals business for $800 million in real money. SERB, supported by private value firm Charterhouse Capital Partners since 2017, possesses an expanded arrangement of doctor prescribed prescriptions zeroed in on uncommon and hazardous infections. "...

Read More

BUSINESS INSIGHTS

TEVA REACHES AGREEMENT WITH TEXAS TO SETTLE THE STATE’S OPIOID-RELATED CLAIMS

Teva Pharmaceuticals | February 08, 2022

news image

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and its affiliates, has reached an agreement with the Attorney General (AG) of Texas that settles the state’s and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Texas $150 million over a 15-year time period and will provide the recently launched, lifesaving medicine generic Narcan®, valued at $75 million over 10 years. “Expan...

Read More

PHARMA TECH

HOVIONE AND ZERION PHARMA ANNOUNCE A STRATEGIC PARTNERSHIP TO MARKET THE DISPERSOME® TECHNOLOGY PLATFORM

Hovione | February 23, 2022

news image

Hovione, the leader in spray drying and particle engineering, announced a strategic partnership with Zerion Pharma to market and commercialize Dispersome®, Zerion´s proprietary solubility enhancement technology platform. Zerion´s innovative Dispersome® technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying. By combining Dispersome® t...

Read More
news image

GILEAD, WORKING ON ITS OWN REMDESIVIR RAMP-UP, SCOUTS LICENSING PARTNERS FOR GLOBAL PRODUCTION

Fiercepharma | May 06, 2020

Gilead Sciences can only produce so much of its newly authorized COVID-19 drug remdesivir, so it’s scouting other companies to bolster global supply. Even as it presses ahead with its own remdesivir ramp-up, Gilead says it’s in licensing talks with the “world’s leading chemical and pharmaceutical manufacturing companies” about their ability to produce remdesivir for countries in Europe, Asia and beyond until at least 2022. Remdesivir manufacturing relies on “s...

Read More
news image

PHARMACY MARKET

BOSTON SCIENTIFIC ANNOUNCES PARTNERSHIP DEFINITIVE AGREEMENT TO DIVEST BTG SPECIALTY PHARMACEUTICALS BUSINESS

Boston Scientific | December 02, 2020

Boston Scientific Corporation today declared that it has gone into a conclusive concurrence with Stark International Lux S.A.R.L., and SERB SAS, partners of SERB, an European strength drug gathering, to sell its BTG Specialty Pharmaceuticals business for $800 million in real money. SERB, supported by private value firm Charterhouse Capital Partners since 2017, possesses an expanded arrangement of doctor prescribed prescriptions zeroed in on uncommon and hazardous infections. "...

Read More
news image

BUSINESS INSIGHTS

TEVA REACHES AGREEMENT WITH TEXAS TO SETTLE THE STATE’S OPIOID-RELATED CLAIMS

Teva Pharmaceuticals | February 08, 2022

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and its affiliates, has reached an agreement with the Attorney General (AG) of Texas that settles the state’s and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Texas $150 million over a 15-year time period and will provide the recently launched, lifesaving medicine generic Narcan®, valued at $75 million over 10 years. “Expan...

Read More
news image

PHARMA TECH

HOVIONE AND ZERION PHARMA ANNOUNCE A STRATEGIC PARTNERSHIP TO MARKET THE DISPERSOME® TECHNOLOGY PLATFORM

Hovione | February 23, 2022

Hovione, the leader in spray drying and particle engineering, announced a strategic partnership with Zerion Pharma to market and commercialize Dispersome®, Zerion´s proprietary solubility enhancement technology platform. Zerion´s innovative Dispersome® technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying. By combining Dispersome® t...

Read More